Zoetis Services
Develops, manufactures, and sells animal vaccines
GMP Training Lead
About the job
- A bachelor's degree in Training & Development, Instructional Design, Adult Education, Organizational Development, Learning & Development, Engineering, Biology, Chemistry, Microbiology, Virology, or Immunology.
- At least 5 years of experience in training delivery, training coordination, curriculum development, learning and development, or related training functions, including classroom facilitation and presentation experience.
- Strong technical and analytical skills.
- Familiarity or proficiency with adult learning methodologies.
- Strong technical writing skills.
- Working knowledge of vaccine production methods and experimental design, with experience in good laboratory practice or current good manufacturing practice.
- Knowledge of Food and Drug Administration, Animal and Plant Health Inspection Service, Veterinary Medicines Directorate, and United States Department of Agriculture regulations applicable to the pharmaceutical and biological industry.
- Ability to walk or stand for long periods and perform frequent reaching, bending, stooping, kneeling, pushing, pulling, and gripping.
- Ability to work 40 scheduled hours and overtime as needed, lift and carry 5 to 25 pounds, and perform repetitive wrist, hand, and finger movements.
- Ability to become qualified to enter cleanroom environments.
- Authorization to work in the United States.
- Provide flexible training support across identified functions, delivering startup-to-full-operations training and assuming responsibility for additional training needs.
- Serve as the primary trainer for current good manufacturing practice, current good distribution practice, contamination control, and aseptic behavior for aseptic manufacture of biologic products and materials.
- Design, develop, and implement curricula and conduct training for monoclonal antibody drug-product manufacturing and biologics packaging in compliance with site procedures and global standards.
- Identify and drive continuous process improvements related to good manufacturing practice and aseptic training.
- Improve and innovate training execution and management, and conduct audits and reviews of personnel to evaluate training effectiveness.
- Administer the Learning Management System using SAP SuccessFactors.
- Facilitate new employee orientation, including current good manufacturing practice, current good distribution practice, current good laboratory practice, and aseptic training for initial and refresher training.
- Conduct gowning qualification and classroom process simulations.
- Coordinate required annual training with department management.
- Conduct spot checks and audits of aseptic techniques and behaviors during operations.
- Observe aseptic process simulations, including media fills, for aseptic practices and best practices.
- Network with the Global Aseptic Team to share best practices.
- Liaise with colleagues to ensure they are trained and understand the criticality of the aseptic process work they conduct.
- Coordinate personnel training using available technology, including virtual reality technology.
- Integrate training sessions and training documentation into electronic training document management systems.
- Collaborate with area Operations Team Leaders to train and lead colleagues in performing best practices.
- Collaborate with Quality Control to analyze training techniques and instructions for error-prone testing.
- Collaborate with Quality Assurance to analyze training techniques and instructions for incidents with patterns and trends.
- Use subject-matter knowledge related to aseptic processing to conduct training covering good manufacturing practice and regulatory requirements, compliance trends and data integrity, basic industrial microbiology, facility design and environmental controls, cleaning and disinfection, aseptic and controlled-area gowning, good aseptic technique, material transfer, material and personnel and equipment flow, isolator and barrier systems, sterilization and validation, and bioburden reduction.
- Experience in aseptic and biological product formulation, including blending, filling, or lyophilization, packaging, and/or testing.
- Preferred experience in Lean/Six Sigma.
About the company
Zoetis creates medicines and vaccines to protect the health of companion animals and livestock. Its products include vaccines, anti-infectives, parasiticides, dermatology and other therapeutics, medicated feed additives, and diagnostics, sold through veterinarians, livestock producers, and pet owners. The company reaches customers in more than 100 countries and relies on big R&D and a global marketing network to bring new solutions to market. Its goal is to improve animal health worldwide by delivering science-based products and services that help care for animals and prevent disease.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parsippany-Troy Hills, New Jersey
Founded
1952
Get referred to Zoetis Services
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA granted Simparica Trio EUA on August 13, 2026 for screwworm in dogs.
- Livestock revenue grew double digits in 2026, led by cattle, poultry, and fish.
- Lenivia and Portela launches in Canada and Europe expand osteoarthritis pain coverage.
What critics are saying
- U.S. companion-animal revenue fell 7% in Q2 2026 as clinic visits weakened.
- Elanco and Merck are squeezing Apoquel and Simparica with promotions through 2027.
- If dermatology share keeps eroding, Zoetis becomes a slower livestock-and-diagnostics utility.
What makes Zoetis Services unique
- Zoetis dominates veterinary channels with a broad companion-animal and livestock portfolio.
- Its pipeline spans renal disease, oncology, cardiology, and dermatology, unlike commodity peers.
- Global reach across 100-plus countries gives Zoetis pricing power and distribution leverage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 15%1 year growth
↑ 15%2 year growth
↑ 15%CooperVision appoints new global director for global myopia management. 22 September 2026 Chris Dimmack joins CooperVision as senior director, global myopia management, moving from Zoetis, where he was head of sales. He previously spent close to 18 years at Johnson & Johnson, most recently as commercial business manager. Jennifer Lambert, who held the same position at CooperVision, was promoted to the vice... Subscribe today. Buying a membership today will give you: * Unlimited access to ewintelligence.com - all insight and analysis available online * Its executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry * Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments * Case studies and best practices on business challenges * Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry * Access to over 11,500 articles and analyses in the archive * Personal library to save articles and track your key content * Powerful search and intuitive navigation * Organisation-wide access across offices, people and devices
The AVA secures $150,000 Zoetis Foundation grant. The Australian Veterinary Association (AVA) has received a USD $150,000 grant from the Zoetis Foundation to expand its Cultivating Safe Teams program nationwide. The funding will support the AVA's goal of training every veterinary professional in Australia to identify and manage psychosocial risks in the workplace. More than 1,300 veterinary professionals have completed the training since it launched in 2023. Cultivating Safe Teams is the flagship program under the AVA's THRIVE wellbeing initiative, which targets psychological harm in veterinary workplaces. Dr Diana Barker, President of the AVA, said the grant would allow the organisation to broaden the program's reach. "Veterinary teams do extraordinary work under real pressure, and for too long the toll of that pressure has gone unaddressed. "This grant enables us to take a program that works and put it in front of every veterinary professional in the country." The program grew out of the AVA's 2021 Veterinary Stakeholder Wellness Survey, which found two in three veterinary professionals had experienced a mental health condition, and almost half said their work was harming their mental health. Cultivating Safe Teams runs as a one-hour awareness session built around evidence-based workplace psychological health and safety frameworks, designed to fit around busy clinic schedules. Among participants, 93 per cent rated the session useful and 94 per cent rated it relevant, while confidence in identifying psychosocial hazards rose by 60 per cent. Dr Barker explained that proactive management of psychosocial risk is now the law in every Australian jurisdiction, so there has never been a more important time to act. "This is about more than compliance. It is about building workplaces where people are safe, supported and want to stay, and that is good for our people, our patients and the future of the profession." The AVA is now expanding the program beyond awareness-raising with a new offering, CST ACTION, which trains workplace champions to run a validated risk assessment and design initiatives tailored to their own hazard profile. The offering includes coaching from organisational psychologists, self-paced modules and peer-to-peer learning. Expressions of interest for the 2027 program are open now on the AVA website. Jeannette Ferran Astorga, Executive Vice President of Corporate Affairs at Zoetis and President of the Zoetis Foundation, said the funding reflected the company's commitment to the sector. "The veterinary profession is foundational to animal health, and the professionals caring for animals deserve workplaces that protect their wellbeing. "We are proud to support the AVA in scaling a program that is already making a measurable difference to veterinary teams across Australia." Cultivating Safe Teams is delivered with support from the Zoetis Foundation, Crampton Consulting Group, Hill's Pet Nutrition and Troy.
Zoetis stands by guidance as pet-care weakness and competition pressure sales. September 18, 2026 Key points. * Zoetis maintained its revised guidance for operational revenue declining 3% to 1%, citing weaker U.S. pet-care demand, fewer veterinary visits and intensified competition in dermatology and parasiticides. * The company is using targeted, time-limited promotions to defend market share rather than broadly cutting prices. Apoquel retained about 87% U.S. share, while parasiticide share declined roughly 1% in the latest quarter. * Future growth opportunities include renal disease, oncology and livestock, with a potential renal treatment approval expected late next year and livestock revenue growing at a double-digit pace. * MarketBeat previews the top five stocks to own by October 1st. Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kristin Peck said the company's revised operational revenue outlook of negative 3% to negative 1% reflects both industry conditions and company-specific competitive dynamics. Zoetis had previously forecast operational revenue growth of 2% to 5%. "For the first time, we saw a declining pet care market," Peck said, pointing to lower veterinary visits and affordability challenges for pet owners. She said parasiticides declined 6.7% industrywide, while demand has been stronger in diagnostic testing and products associated with specialty, urgent and critical care. Targeted promotions and competitive pressure. Peck characterized the company's current pricing pressure as cyclical rather than structural. Zoetis has not broadly reduced list prices for its key dermatology and parasiticide products, she said. Instead, the company has used targeted, time-limited promotions and discounts intended to win business from customers using competing products. "This isn't everybody, 10% discount for anyone who wants to buy," Peck said. "This is, you're buying my competitor's product today, we want to be your parasiticide of choice." The company began many of those targeted programs in the second quarter and made them more aggressive in the third quarter after initial promotions did not deliver the desired results. Peck said Zoetis will assess the programs each quarter and adjust their scope and intensity as needed. She said the company is pleased with the early performance of the actions, while noting that competition can prompt responses from rivals. Zoetis is seeking to protect market share, particularly in categories where it historically held dominant positions, while also using its broad product portfolio and pipeline to support relationships with veterinarians and corporate veterinary customers. Discover more Dividend Screener Tool Compare Investment Apps Jay Saccaro, Zoetis' recently appointed CFO and COO, said he was attracted to the company by its leadership position, commercial capabilities and innovation pipeline. After several weeks in the role, he said his initial observations have been "confirmatory," including the strength of the company's products and the engagement of its employees. Saccaro said the company's assumptions about market conditions are tracking as expected and that management remains confident in guidance. Zoetis plans to update investors in November. Parasiticides, dermatology and product pipeline. In parasiticides, Peck said Zoetis remains the U.S. market-share leader, with nearly twice the share of the next competitor. The company's share declined about 1% during the prior quarter, which she described as relatively stable amid competitive activity. Zoetis continues to see an opportunity to expand the parasiticide market by converting customers from single agents, collars and topical products to triple-combination products. International markets also remain a growth opportunity, Peck said, citing the recent launch of Simparica Trio in Brazil. In dermatology, Zoetis faces a third entrant competing against Apoquel. Peck said the company finished the quarter with approximately 87% U.S. share for Apoquel, while acknowledging that its historically high share will decline as competitors enter. Zoetis expects an approval for long-acting Cytopoint Plus in the U.S. by year-end and continues to promote Apoquel Chewable, Apoquel and Cytopoint as a differentiated portfolio. Peck said Apoquel's first loss of exclusivity is expected in 2032, excluding the chewable formulation. She also highlighted an estimated 16 million untreated dogs in the U.S. with dermatological conditions as an opportunity to expand treatment. Management expects the penetration of newly launched dermatology products to take roughly 18 months historically, though Peck said the pace could vary. Zoetis is watching both share movements and a potential recovery in the broader pet-care market to determine when promotional spending can normalize. Renal disease, oncology and livestock growth. Zoetis identified chronic kidney disease, oncology, cardiology, anxiety, diabetes and obesity as important pipeline opportunities. Peck said renal disease is the nearest-term and largest of those opportunities, describing an approximately $3 billion addressable market. The company has a renal product targeted for approval at the end of next year that is intended to slow disease progression, along with planned diagnostics, biomarkers and additional therapies. Peck said roughly 20% of dogs and 40% of cats develop renal or chronic kidney disease. Zoetis also has two oncology products in its pipeline, including one management believes could become a blockbuster product, defined by the company as one with potential annual sales of $1 billion. The company expects oncology therapies will need to be suitable for use by general veterinary practitioners, in addition to specialists. Meanwhile, livestock has produced double-digit growth this year, according to Peck. She attributed the strength partly to higher protein consumption in developed markets associated with GLP-1 medicines. Growth has extended across species, with fish and poultry the fastest-growing globally and continued strength in U.S. beef and dairy cattle. Zoetis has also reduced list prices for Cerenia and Convenia in response to generic competition, a structural pricing action distinct from its targeted promotions in dermatology and parasiticides. Peck said the company does not expect other large products to face generic competition before 2032. About Zoetis (NYSE:ZTS). Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity. The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Zoetis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list. While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat
Zoetis Inc. (ZTS), the world's leading animal health company, has significantly underperformed the S&P 500. The stock has plunged 39.5% year-to-date and 50.2% over the past year, whilst the S&P 500 gained 12% and 19.5% respectively during the same periods. The Parsippany, New Jersey-based company, which develops vaccines and medicines for companion animals and livestock, currently trades 50.9% below its 52-week high of $155.15. The underperformance stems from sluggish 2.7% annual revenue growth over two years and projected sales declines. Despite market challenges, Zoetis reported Q2 adjusted earnings per share of $1.87, beating Wall Street's $1.86 estimate, though revenue of $2.50 billion missed the $2.51 billion forecast. The company maintains a market capitalisation of $31.9 billion.
Zoetis, an animal health company, has drawn attention from investor Michael Burry, who is long the stock according to Substack disclosures cited by media outlets. The shares have fallen roughly 40% this year and over 70% from their 2021 peak. Competition from Elanco and Merck in dermatology and parasite treatments has pressured results. In fiscal Q2 2026, revenue was roughly flat, with US sales down 7% whilst international revenue grew 6%. The stock now trades near 12 times forward earnings, compared with a historical average of 30 times. Zoetis maintains around 86% of the US pet skin drug market, with gross margins above 70%. Wall Street analysts remain mostly bullish, with consensus price targets suggesting roughly 70% upside potential.